Seagen | 142.8500 / -1.12% |
Date/Time | 04/09 / 22:00 |
Chg. / Chg.(%) | -1.6200 / -1.12% |
Bid | 142.7100 / 13200 |
Ask | 147.0100 / 200 |
Open | 143.9500 |
Previous Close | 144.4700 |
High | 144.3250 |
Low | 140.8300 |
Volume [USD] | 50,629,461.1580 |
Volume [Units] | 497,744 |
Price fixings | 1876 |
ISIN | US81181C1045 |
Security | SGEN |
Exchange | NASDAQ |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 118.84 | ![]() |
|
NASDAQ | 142.8500 | ![]() |
497,744 |
IEX | 142.89 | ![]() |
31,178 |
Cboe US | 142.84 | ![]() |
12,727 |
TradeGate | 119.00 | ![]() |
74 |
München | 119.06 | ![]() |
0 |
Berlin | 119.16 | ![]() |
0 |
Frankfurt | 119.8600 | ![]() |
0 |
Stuttgart | 119.860 | ![]() |
0 |
gettex | 120.000 | ![]() |
|
Mexico | 3,192.00 | ![]() |
21 |
News
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Fight Colorectal Cancer Urges Americans, “No Excuses! Get Screened!” after 10,000 excess cancer deaths are expected over the next decade
03/02/2021 / 20:58 - GlobeNewswire - Genmab Publishes 2020 Annual Report
02/23/2021 / 17:00 - GlobeNewswire - US opens lower ahead of economic updates
02/12/2021 / 15:30 - TeleTrader - Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
02/10/2021 / 22:05 - GlobeNewswire